The CBX6 Knockout A2780 Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal knockout population targeting the CBX6 gene in A2780 human ovarian carcinoma cells. This loss-of-function model enables investigation of CBX6-dependent epigenetic regulation and gene silencing. The polyclonal format offers a heterogeneous editing landscape without single-cell clonal selection, suitable for population-level functional assays exploring Polycomb-mediated repression.
The A2780 parental cell line, derived from an untreated human ovarian endometrioid adenocarcinoma, is widely used as a model for ovarian cancer research. It retains epithelial morphology and supports adherent growth, making it compatible with assays that assess proliferation, migration, and response to chemotherapeutic agents such as cisplatin.
CBX6 is a core component of canonical PRC1, recognizing H3K27me3 via its chromodomain to mediate chromatin compaction and gene silencing. It interacts with RING1A, RING1B, BMI1, and PHC1, and its expression is regulated by the E2F1 transcription factor and promoter DNA methylation. CBX6 represses transcription of tumor suppressors CDKN2A and CDKN1A, HOX family genes, and epithelial-mesenchymal transition markers E-cadherin and Vimentin, thereby influencing Wnt signaling and cellular senescence. The H3K27me3 mark is deposited by the PRC2 complex containing EZH2, SUZ12, and EED, establishing a repressive chromatin landscape recognized by CBX6.
In the A2780 ovarian carcinoma model, loss of CBX6 impairs PRC1 occupancy at target loci, leading to derepression of CDKN2A and CDKN1A and consequent cell cycle arrest and senescence-like phenotypes. Altered expression of E-cadherin and Vimentin modulates epithelial-mesenchymal transition, potentially reducing invasive capacity. This functional reprogramming highlights the role of CBX6 in maintaining the oncogenic epigenetic state of ovarian cancer cells and provides a relevant system for dissecting Polycomb-dependent tumorigenesis.
These cells are ideal for epigenetic regulation studies, PRC1 complex functional analysis, tumor suppressor reactivation research, and ovarian cancer drug target identification. Typical assays include Western blotting for CBX6 and H3K27me3, RT-qPCR for CDKN2A, CDKN1A, and HOX genes, ChIP-qPCR, immunofluorescence, flow cytometry for cell cycle distribution, MTT/BrdU proliferation assays, transwell migration assays, and cisplatin sensitivity testing. The polyclonal knockout format allows assessment of bulk population responses, suitable for high-throughput screening or pooled functional genomics. For further technical assistance and customized solutions, please contact Ascent Research.
